Metformin has multiple benefits in sporadic AD, reducing Aß levels and tau hyperphosphorylation [167–172], increasing neuronal density and alleviating hippocampal histopathological alterations, preserving Nissl bodies in various models [167, 168, 172–177]. The gene discussed is MAPT; the disease is Alzheimer disease.